http://chineseinput.net/에서 pinyin(병음)방식으로 중국어를 변환할 수 있습니다.
변환된 중국어를 복사하여 사용하시면 됩니다.
Shinichi Tate,Kyoko Nishikimi,Ayumu Matsuoka,Satoyo Otsuka,Kazuyoshi Kato,Yutaka Takahashi,Makio Shozu 대한부인종양학회 2021 Journal of Gynecologic Oncology Vol.32 No.1
Objective: We investigated the efficacy and toxicity of tailored-dose chemotherapy withgemcitabine and irinotecan for platinum-refractory/resistant ovarian or primary peritoneal cancer. Methods: We enrolled patients with ovarian or primary peritoneal cancer who received ≥2previous chemotherapeutic regimens but developed progressive disease during platinum based chemotherapy or within 6 months post-treatment. All patients received gemcitabine(500 mg/m2) and irinotecan (50 mg/m2) on days 1 and 8 every 21 days at the starting dose. Thedose was increased or decreased by 4 levels in subsequent cycles based on hematological ornon-hematological toxicities observed. The primary endpoint was progression-free survival(PFS), and secondary endpoints were disease control rate (DCR), overall survival (OS), andadverse events. Results: We investigated 25 patients who received 267 cycles (median 8 cycles/patient)between October 2008 and May 2011. Tailored-dose gemcitabine was administered up to the5th cycle as follows: 1,000 mg/m2in 1 (4%), 750 mg/m2in 16 (64%), 500 mg/m2in 6 (24%),and 250 mg/m2in 2 patients (8%). The median PFS and OS were 6.2 months (95% confidenceinterval [CI]=2.7–10.7) and 16.8 months (95% CI=9.4–30.7), respectively. The DCR was 76%,and PFS was >6 months in 12 of 25 patients (48%). Grade 3 hematological toxicities includedleukopenia (9.4%), neutropenia (11.2%), anemia (9.8%), and thrombocytopenia (1.1%). Grade 3/4 non-hematological toxicities did not occur except for fatigue in one patient. Conclusions: Tailored-dose chemotherapy with gemcitabine and irinotecan was effective andwell tolerated in patients with platinum-refractory/resistant ovarian or primary peritoneal cancer. Trial Registration: UMIN Clinical Trials Registry Identifier: UMIN000004449
Shinichi Tate,Kyoko Nishikimi,Kazuyoshi Kato,Ayumu Matsuoka,Michiyo Kambe,Takako Kiyokawa,Makio Shozu 대한부인종양학회 2020 Journal of Gynecologic Oncology Vol.31 No.3
Objective: This study aimed to evaluate the presence of pathological residual tumor (pRT) in each initial disseminated site after neoadjuvant chemotherapy (NACT) to assess the appropriate surgical margins during interval debulking surgery (IDS) for a favorable prognosis. Methods: This prospective descriptive study included patients with stage IIIC–IV epithelial ovarian, fallopian tubal, and peritoneal cancer. One hundred eleven patients underwent diagnostic exploratory laparotomy, and their initial intra-abdominal dissemination statuses were recorded. Any tumor >1 cm in diameter found during the exploratory laparotomy was resected during IDS even if it was macroscopically invisible after NACT. The pRT rate after NACT and negative predictive value (NPV; probability that sites with macroscopically invisible tumors have no pRT) during IDS were assessed in each disseminated site. Results: A median of 5 NACT cycles were performed. Sites with a high incidence of pRT and low NPV included the rectosigmoid colon (71.4%, 38.6%), transverse mesentery (70.3%, 50.0%), greater omentum (68.3%, 51.7%), right diaphragm (61.9%, 48.1%), paracolic gutters (61.1%, 50.0%), and vesicouterine pouch (56.6%, 50.0%). Organs/tissues with a high incidence of pRT featured a low NPV. The median progression-free survival and overall survival in this cohort were 27.7 and 71.9 months, respectively. Conclusion: Even if a disseminated site >1 cm in diameter before NACT is invisible during IDS, microscopic disease remains present within it. The appropriate surgical margins for IDS with a favorable prognosis could be secured by resecting a lesion of >1 cm before NACT even if it is invisible during IDS.
VTOL mode controller for a mini-UAV having a side-force fin
Shinichi Hashimoto,Nobuhiro Yokoyama,Yoshimasa Ochi,Hideo Adachi,Natsuki Kondo,Toshiaki Yamashita,Takanari Arai 한국항공우주학회 2008 한국항공우주학회 학술발표회 논문집 Vol.- No.-
A UAV (Unmanned Aerial Vehicle) currently developed by the authors is a kind of flying wing. One of features of the UAV is its capability of vertical takeoff and landing as a tail-sitter. Thus, it is possible to operate it flexibly by reducing the space restrictions on the takeoff and landing. In this work, we designed a gain-scheduled controller for the vertical takeoff and landing, which can vary the control gain in accordance with the varying state of the vehicle. We applied a method that solves Lyapunov stability conditions on all the design points simultaneously by using linear matrix inequalities (LMI). The effectiveness of the controller is demonstrated through the numerical simulations.